Skip to content

    Recently Viewed



      What you need to know about Johnson & Johnson’s 2022 third-quarter earnings

      Check out this infographic breakdown of the company’s third-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

      Share Article
      share to
      Inset - Quarterly Earnings Ribbon

      This morning, Johnson & Johnson shared its third-quarter performance.

      Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

      “The solid results delivered this quarter, including accelerated operational sales* growth in all three of our segments, reflect the strength of our business, versatility of our operations, and the unwavering commitment of Johnson & Johnson’s employees to patients and consumers around the world,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “We invested in R&D at increased levels, advanced our pipeline and returned significant value to shareholders. Looking ahead, we will continue to execute against our long-term strategy, focused on improving health outcomes and access to care.”

      For more details about the company’s 2022 third-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.

      *Non-GAAP financial measure. Refer to the reconciliations in the full press release.

      Q3 2022 Earnings IG

      Johnson & Johnson’s 2022 3rd-Quarter Earnings

      Read the earnings press release, which includes full financial data for the third quarter of 2022.

      Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

      More from Johnson & Johnson

      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      Health & wellness
       Blue latex gloved hand pointing at a brain MRI scan to pinpoint brain circuits associated with depression symptoms

      Is this the end of one-size-fits-all treatments for depression?

      Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.